TONIX PHARMACEUTICALS HOLDIN (TNXP)

Company Profile

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. The company is headquartered in Chatham, New Jersey and currently employs 117 full-time employees. The company went IPO on 2010-03-29. The firm is focused on developing therapeutics and vaccines to treat and prevent human disease and alleviate suffering. The company markets Zembrace SymTouch (sumatriptan injection) 3 mg and Tosymra (sumatriptan nasal spray) 10 mg. Its portfolio consists of central nervous system (CNS), rare disease, immunology, and infectious disease product candidates. The CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Its immunology portfolio includes biologics to address organ transplant rejection, autoimmune diseases and cancer. Its infectious disease portfolio includes a vaccine in development to prevent smallpox and mpox, vaccines to prevent COVID-19, a platform to make fully human monoclonal antibodies (mAbs), to treat COVID-19 and humanized anti-SARS-CoV-2 mAbs. Its product candidates include TNX-102 SL, TNX-4300, TNX-1900, TNX-601 ER and others.

Company Info

TONIX PHARMACEUTICALS HOLDIN

26 Main Street, Suite 101

Chatham NEW JERSEY 07928

P: 12129809155

CEO: Seth Lederman

Employees: 117

Website: https://www.tonixpharma.com/